We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

98 hedge funds and large institutions have $556M invested in Revance Therapeutics, Inc. in 2014 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 40 increasing their positions, 17 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,100% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 3

135% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 17

49% more capital invested

Capital invested by funds: $373M → $556M (+$183M)

48% more funds holding

Funds holding: 66 → 98 (+32)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
98
Holders Change
+32
Holders Change %
+48.48%
% of All Funds
2.82%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
36
Increased
40
Reduced
17
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
+$29.6M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$21.9M
3
ACH
ArrowMark Colorado Holdings
Colorado
+$13M
4
JP Morgan Chase
JP Morgan Chase
New York
+$12.7M
5
AllianceBernstein
AllianceBernstein
Tennessee
+$11.7M

Top Sellers

Rank Fund Capital Flow
1
VAM
Visium Asset Management
New York
-$16.8M
2
ZDA
Zweig-DiMenna Associates
New York
-$6.41M
3
Millennium Management
Millennium Management
New York
-$6.29M
4
WRF
Waddell & Reed Financial
Kansas
-$4.67M
5
PHS
PFM Health Sciences
California
-$2.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
BIT
26
BlackRock Institutional Trust
California
$4.1M -$968K -30,893 -20%
Millennium Management
27
Millennium Management
New York
$4.1M -$6.29M -200,609 -62%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$3.72M +$2.86M +91,133 +498%
PC
29
Pier Capital
Connecticut
$3.64M +$3.35M +106,985 New
MCM
30
Moore Capital Management
New York
$3.4M +$3.13M +100,000 New
PAI
31
Palo Alto Investors
California
$3.12M – – –
State Street
32
State Street
Massachusetts
$3.1M +$806K +25,734 +39%
ZDA
33
Zweig-DiMenna Associates
New York
$2.89M -$6.41M -204,646 -71%
WSA
34
Wall Street Associates
California
$2.79M -$304K -9,700 -11%
RPAM
35
Rhenman & Partners Asset Management
Sweden
$2.79M +$1.03M +32,865 +67%
Northern Trust
36
Northern Trust
Illinois
$2.54M +$1.44M +45,973 +161%
HCMT
37
Highland Capital Management (Texas)
Texas
$2.48M +$2.28M +72,866 New
SM
38
Sabby Management
Florida
$2.29M +$2.11M +67,200 New
Principal Financial Group
39
Principal Financial Group
Iowa
$2.28M +$220K +7,035 +12%
UBS AM
40
UBS AM
Illinois
$2.22M +$530K +16,900 +35%
NIP
41
Nicholas Investment Partners
California
$2.05M +$1.89M +60,255 New
Alyeska Investment Group
42
Alyeska Investment Group
Illinois
$2.04M +$1.88M +60,000 New
BA
43
BlackRock Advisors
Delaware
$1.99M +$279K +8,916 +18%
TG
44
TCW Group
California
$1.99M +$448K +14,291 +32%
EI
45
EAM Investors
California
$1.79M +$1.65M +52,668 New
GPCM
46
Granite Point Capital Management
Massachusetts
$1.7M +$890K +28,400 +131%
GACM
47
Green Arrow Capital Management
New York
$1.7M +$1.57M +50,000 New
Schroder Investment Management Group
48
Schroder Investment Management Group
United Kingdom
$1.7M +$1.57M +50,000 New
Geode Capital Management
49
Geode Capital Management
Massachusetts
$1.39M +$182K +5,806 +17%
PAM
50
Panagora Asset Management
Massachusetts
$1.26M -$45.6K -1,455 -4%
1
2
3 4 5

RVNC Hedge Fund Activity: Q2 2014 in Review

98 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q2 2014, worth a combined $556M — up 49% from $373M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new RVNC positions and 3 closed out — a net gain of 33 holders — while 40 added to existing stakes and 17 trimmed.

The largest buyer was Jennison Associates, adding an estimated $29.6M. The largest seller was Visium Asset Management, cutting an estimated $16.8M.

  • 98 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q2 2014, up from 66 in Q1 2014.
  • Funds reported $556M of Revance Therapeutics, Inc. stock for Q2 2014, up 49% quarter-over-quarter.
  • 36 funds opened new Revance Therapeutics, Inc. positions in Q2 2014 and 3 closed out, a net change of +33 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q2 2014 was Jennison Associates, an estimated $29.6M added.
  • The largest Revance Therapeutics, Inc. seller in Q2 2014 was Visium Asset Management, an estimated $16.8M sold.

Based on aggregated 13F filings for Q2 2014.